All News
#ACR20 Abs#L11. Efficacy of TOFA vs PBO in AS. At week 16, %ASAS20 responders 56% v 29% PBO; %ASAS40 40% vs 12%. @RheumNow #ACRBest https://t.co/3Faj64rBjd
Eric Dein ejdein1 ( View Tweet)
Large cohort of older RA pts newly rx w/HCQ or MTX:
👉~2-fold ⬆ risk of VTE – both PE and DVT- among patients newly treated with MTX vs. HCQ.
@RheumNow #ACR20 abs#2000 @DanielHSolomon https://t.co/ZnDuMhTMYF
sheila RHEUMarampa ( View Tweet)
"The goal of a vaccine is not just to protect a (vaccinated) individual, but to end the pandemic." Dr. Dan Barouch #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
HCQ not associated with ⬆ incidence of cardiac dse in this cohort of RA pts.
We should continue using it. Benefits >>>risks.
@RheumNow #ACR20 abs1999 https://t.co/zYpbX0CsR1
sheila RHEUMarampa ( View Tweet)
Industry Abstract Previews - #ACR20
https://t.co/IiF0Md8XXk https://t.co/7qmqwQcgOa
Links:
Dr. John Cush RheumNow ( View Tweet)
What a great interview with @IreneBlancoMD regarding equity and inclusion in rheumatology. She is amazing! Such an important topic for all of us! #ACR20 @rheumnow https://t.co/cmRfXVGGDJ
Dr. Rachel Tate uptoTate ( View Tweet)
Listen to part IIII of our #ACR20 Day 3 recap. Follow the link below or find us on Apple podcasts.
https://t.co/cI9UGyFwIJ https://t.co/NiTeNxsGaD
Links:
Dr. John Cush RheumNow ( View Tweet)
We as young physicians should start paying attention to our contracts-🤦♀️ takeaways
1-know your worth (see MGMA compensation yearly)
2-malpractive/ tail coverage
3-non-compete
4-termination clause
5-gurantee
@RheumNow #ACR20 #5M036
Bella Mehta bella_mehta ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Gender disparity in Ankylosing Spondylitis symptoms.
1⃣Women ⬆️Achilles tendonitis, plantar fasciitis, joint swelling, BASDAI>40, DMARD use
2⃣HLA-B not associated w/ enthesitis
@RheumNow #ACR20 Abs#1872 https://t.co/bxiNUjY1Xh
Robert B Chao, MD doctorRBC ( View Tweet)
NEW ACR2020 Draft Guidelines for the Pharmacologic Treatment of RA
All the guidelines in 2 tables!
1. MTX 1st, oral > SC
2. Minimize GC!
3. TTT TTT TTT
4. Biologic/tsDMARD > Triple Tx
5. Taper MTX 1st
Close to my practice; suspect will be controversial!
#ACR20 #ACRambassador https://t.co/iFSlq1H65V
Mike Putman EBRheum ( View Tweet)
Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow
David Liew drdavidliew ( View Tweet)
IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020
Dr. John Cush RheumNow ( View Tweet)
Following the results of the FAST trial, would you have any concerns about prescribing febuxostat if clinically indicated?
#ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Just as a reminder of how we felt back then.
https://t.co/onIMqa5DAp
Also note, the hypogammaglob gap has widened a little (then 25 v 21, now 36 v 26).
Now we have the extended follow-up data, where no additional benefit was noted, do we still feel that excited? #ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Improvement of enthesitis US scores consistent with bDMARD initiation/change
1⃣MASEI and OMERACT scores improved at 3 mo/6mo
2⃣Associated with clinical activity outcomes
@RheumNow #ACR20 Abs#1552 https://t.co/qnSEBaXrJo
Robert B Chao, MD doctorRBC ( View Tweet)
RITZAREM
(RTX vs AZA maintenance post RTX induction relapsing AAV)
what happened post-study?
After #ACR19, hope RTX confers ongoing benefit
Answer: no. Same decline
Is 1g q4m dosing not justified?
Does that mean RTX needs to be continued, and in whom?
#ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC
David Liew drdavidliew ( View Tweet)
Did you have diversity and inclusion and/or bias training during fellowship? #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
GOUT: CARES study says febuxostat has high CV risk, new FAST study says no incr risk. Would you give FEB to a gout pt w/ CV risk?
Dr. John Cush RheumNow ( View Tweet)
When diagnosing Febrile, possible autoinflammatory, Stills disorders do you order genetic testing
Dr. John Cush RheumNow ( View Tweet)